GSK poach­es new drug de­vel­op­ment chief Chris Cor­si­co from Boehringer, di­vid­ing R&D in­to two groups

Glax­o­SmithK­line is con­tin­u­ing its makeover in the ex­ec­u­tive team that runs its R&D group.

The phar­ma gi­ant tells me that Chris Cor­si­co, who had been chief med­ical of­fi­cer at the pri­vate Ger­man out­fit Boehringer In­gel­heim, is step­ping over to GSK as the head of drug de­vel­op­ment, putting him in a new, top po­si­tion for ham­mer­ing out the clin­i­cal plans that the phar­ma gi­ant is putting in­to place un­der R&D chief Hal Bar­ron. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA